Chronic bronchiti\ is per\istclit inflamnicition xi3 irritation of the bronchial tree \xrhich is clmically d e f i n d as hymptoiiis of cough with sputum production 2S42
INTRODUCTION
Loxver respiratory tract infections (LILTIS) arc 3111011g the most coninion infections in humans, comprising ~ippi-oximxely 13'% and 2.5% of , 111 coiiimunityacquired m d nosocomial infections, respectively [ 11. Exly diagnosis ic often essential to avoid the sexwe morbidity 'ind the risk of hospitalization mociated \vith ii)'iiiy LRTIs. Identification of the relevmt pcdiogene before antibiotic therapy is initiated is still probleiiiatic, hoLvever. and treatment is frequently eiiipiricd. Consequently, antibiotics with a spectrum adapted to the range of pulmonary pathogens :ire generally preferred.
The ability to penetrate into pulmonary tissuec, cells, and fluids, reaching concentrations which inhibit 01-kill the cmsxive organisms, \eeiiis t o be 'in iniportant charcicteri~tic of the ideal mtiniicrobial agent for the tresitment of LILTIS. although its cliiiic,il I-elevmcr in human\ h a c not been fully cissewd. Fluoroquinoloiirs penetrate very \veil into the lung, a i d may 'ichieve bronchial and pulmonary concentr.itioiis that equal or exceed ceruiii coticeiitrsitions [ 21. I n xidition, ~ntracellular coiicentratioiis <ire 'ilso within the thercipeutic range fixthe niajority of intracellular pathogens causing LRTls. Converwly, most p-I'ictani mtibiotics do not exceed 30'% of their serum level within bronchial secretions. and some agents, such n\ miinoglycosides, only re'icli 30-40'X of their seruni level in the lung, m d less in the inter-m d intracell~il~ir milieu [2, 3] .
There i\. 'it present, ' 1 geiier~l trend to reduce thc duration of therapy in order to reduce the possible developnient of adverse events a i d resistmce, xvhilst niaintaiiiing clinical ef'fcacy, and to improve the costetfectiveness of treatnient a n d decrease hospit'ilization time. Also iinportant is the increasing use of step-down or switch therapy, \171iereby treatiiient if \tarted with intravenous ,idmi~iisti-ation and then continued Ivith an oral foriiiulation 111. Thi\ h,is s e w r d adv'intages, 111cluding pl~armacorconoii~ic ~dvxitages ~n d iinpi-ovcci patient c-oiiiplimce. This paper focuscs on the c'iusativc pcithogerir 111 LILTIS. the current approaches t o trcatnient, nnd the experience to datc with fluorocluiilolones. Although the ~i s e of soiiie fluorocluiiioloiie\. p t i c u l a r l y ciprofloxacin, iii the ti-e~tiiient of c> ctic fibrosis i\ xvell docuniciited. the topic \ v x i i o t di\cur\ttd 'it thi5 nicctiiig, \vhich \ v~e foc-uwd 011 t h c treatment o f infections in adult pitient\. 2S43 during 3 consecutive months over 2 consecutive years with periodic acute exacerbations during which \ymptoms worsen [5] . It is generally a progressive condition which is closely linked to smoking, and is most frequently found in older men (> 40 years old). Chronic bronchitis is very common, affecting up to 25% of the adult population. During periods of acute exacerbation, when inflammation and infection are worsened, antibiotic therapy is usually instituted. Signs and symptoms of acute exacerbations include: a change in the amount, consistency and color of the sputum; increased dyspnea; productive cough; tachypnea; chest tightness; increased fatigue; and, especially in the elderly, confusion. In addition, physical examination may reveal rales and ronchi and, at times, prolonged exhalation.
Etiology
The bacterial species commonly associated with acute exacerbations of chronic bronchitis are relatively nonvirulent, usually forming part of the flora of the upper respiratory tract [6] . Non-typeable Huermpki/us influenzue accounts for approximately 70% of isolates from patients with acute exacerbations of chronic bronchitis. The airways are thought to become colonized through interaction between specific bacterial adhesions and epithelial cell receptors [7] . When H . injuenzue is introduced into the respiratory tract, it is normally removed rapidly by mucociliary clearance, but in individuals with impairment of this host defense mechanism it reniains attached longer to pooled mucus, allowing surface contact with areas of damaged bronchial epithelium. Further damage to the epithelium, resulting from bacterial toxins and metabolic products, could help the bacterium to spread through the respiratory tract [6] . Streptococcus pneumoiziae is another commonly encountered bacterium responsible for purulent exacerbation, and Moruxellu cutuYrlzulis may also be implicated in a smaller number of cases [8, 9] . Klebsiella pneumoniue, Stupliylococcus uureus and Pseudoinonus uevugiriosu are infrequent causes. Other bacteria that can be involved in acute exacerbations of chronic bronchitis as either exclusively predominant or mixed pathogens include Neisseria spp., Bordetelln spp., Rliodococci spp. and anaerobes. The role of Mycoplasina pnerrriioniae and Clzlamydiu pnerirnoniue in chronic bronchitis should be considered.
Treatment
Oral penicillins are effective against Gram-positive cocci and bacilli and are used to treat infections caused by penicillin-susceptible pneumococci and streptococci in adults and children [lo] . They are not active against P-lactaniase-producing niicroorganisnis or 'atypical' pathogens. Oral cephalosporins are often used and the oral first-generation cephalosporins (cefalexin, cefadroxil, cefradine and cefaclor) are effective against penicillin-susceptible Gram-positive organisms but show restricted efficacy against penicillin-resistant 
Fluoroquinolones
In the treatment of acute exacerbation of chronic bronchitis, ciprofloxacin (500 ing twice daily) has been shown to be as effective as amoxycillin/clavulanic acid (875 mg/125 mg twice daily) or cefixime (400 nig once daily) in a study of 218 outpatients [ l l ] . Eradication rates of 81%, 82% and 78% were reported with ciprofloxacin, aiiioxycihn/clavulanic acid and cefixime, respectively. Moreover, clinical success was obtained in 86%) of patients treated with ciprofloxacin, 91% of the cases treated with amoxycillin/clavulanic acid, and 81% of the cefixime group.
Ofloxacin has also been shown to be effective [12-141. Chodosh reviewed the use of enoxacin, ciprofloxacin, ofloxacin and temafloxacin in acute exacerbations of chronic bronchitis, and the last three were generally more effective than enoxacin [15] . DeAbate et a1 compared sparfloxacin and ofloxacin in a double-blind study. Overall response rates, defined as cure or iniprovernent of clinical signs and symptoms and eradication or presunied eradication of pathogens, were 85.4% and 88.8%, respectively [16] . The combined eradication and presumed eradication rates were 89.9% and 92.5%, respectively.
The results of two multicenter studies of levofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis are summarized in Table 1 [17, 28] . In the first study, in which levofloxacin was compared with cefaclor, the greatest difference in terms of response of individual pathogens was seen with H. in&renzue (100% versus 71% eradication) [ 171. Eradication rates for Streptococci~s pneuinoniae and Stupliylococcus anreus were 90% and 89%, respectively, for levofloxacin, compared with 86% and 67% for cefaclor. Moreover, overall rates of bacteriologic resistance were 24% in the cefaclor group and 2%) in the levofloxacin group. I n the second study, levofloxacin was found to have comparable efficacy to that of cefuroxirne axetil, with clinical success in 95% of levofloxacin-treated patients and 93% of patients treated with cefuroxime axetil [18] . 
ACUTE BRONCHITIS Definition and diagnosis
Acute bronchitis is characterized by an acute inflaniniation of the bronchi, usually caused by viral infections wch as influenza, rhinovirus or the 'common cold'. In general, it is clinically characterized by the presence of an acute, non-productive cough in patients without underlying lung disease. On the other hand, bacterial infection usually causes fever and soinetinies chills and is usually an acute. severe illness compared with viral infection, which is accompanied by a low fever and milder symptonis in the early stages. Sputum is purulent and plentiful in bacterial infection and rare in viral infection.
Etiology
Acute bronchitis is a viral illness (influenza virus, adenovirus and rhinovirus account for the majority of cases). T h e incidence of primary bacterial infection is difficult to assess. T h e roles of W . ir$iretrzuc and Stveptococcrrs przerrrnorziue are unclear and those of A l pp/n.wu priewnonine, Clilarri ydia prreuvnorria and B. perfussis also need to be considered.
Treatment
Viral respiratory infections usually have a benign course without fever and purulent sputum production. Symptoms decline within 7 day? of onset. Antibiotics are riot usually recommended. In prolonged cases, or documented bacterial infection, p-lactams and macrolides have been used.
NOSOCOMIAL PNEUMONIA
The microbiological etioIoL7 of pneumonia i c extremely variable, depending on whether it is coiiiiiiunity acquired or nosoconiial 1191 T h e virulence of the c'iusative orgcuiisrii 15 the main determinant of the diseaw procecs, although there may be a predisposition to pneunionia cauced by 1 educed hoct defenses, particularly suppression of the cough reflex, impairment of iiiucociliary clearance, the presence of a foreign body or reduced systemic and local immunity.
Definition and diagnosis
Patients with nosoconiial pneunionia usually have 3 variety of severe underlying diseases and are often iiniiiunocoiiiproinised. Thcy a h receive a wide range of medication and supportive management which increases their susceptibility to infectious complication: intubation, in particular, poses an extreme risk for the development of pneumonia. Clinical signs and symptoms are characterized by a sudden onset of malaise, fever, chills, increased sputum production and leukocytosis. In almost all cases, an infiltrate is recognizable on chest X-rays.
Etiology
T h e spectrum of nosocomial pneumonia pathogens includes, in addition to moit bacteria causing community-acquired pneumonia, Gi-an-negative bacteria such as K. prirrrmorrioc, Esclrevicliin coli, ilcinefohactev spp., J? nengiriosa and related organisms, Sfaplzylococcns urirez4s and, occasionally, fungi. However, Gram-negative bacteria are the predominant pathogens, while Stveptoroccru yrreninoriiae and H . ir!fliierizne are not generally considered significant. A polymicrobial etiology is detected in 10-30'X of cases of nosoconiial pneumonia.
Treatment
Nosocomial pneumonia ic the second most important nosoconiial infection. I t prolongs hospital stay and is also associated with substantial mortality. I n niost cases, parenteral drug administration ic ured. T h e choice of antibiotic and dosage regimen vary depending on the spectrum of potential pathogens, and the assessment of a variety of factors, including the severity of the pneumonia, the presence of specific coexisting illness, prior therapy (including mtibiotics), and the duration of hospitalization. Monotherapy with secondgeneration cephalosporins has been shown to be highly successful in cases without severe underlying illness [20] . Patients who belong to special risk groups, such as patients with underlying diseases or elderly patients with pronounced clinical symptoms, are often treated with second-generation cephalosporins in conjunction with aminoglycosides, or ureidopenicillins (piperacillin, azlocillin, mezocillin) in combination with aminoglycosides, or with third-generation cephalosporins, with or without the addition of a macrolide. Erythromycin and other macrolides have good activity against streptococci, pneumococci and Legionella, Mycoplasma and Chlamydia spp. but borderline activity against H . infuenzae [21] . Erythromycin has the disadvantage of a gastrointestinal intolerance rate of up to 30%. The new macrolides have fewer gastrointestinal side effects [22] . For patients with severe concomitant diseases and respiratory insufficiency, third-generation cephalosporins such as ceftazidime, cefepime, cefpirome, ceftriaxone or carbapenems, at high dosage, may be prescribed as monotherapy or in combination with other antibiotics. An alternative therapy in patients who cannot be treated with p-lactams is the use of intravenous and, subsequently, oral fluoroquinoiones.
Fluoroquinolones
Ciprofloxacin has been shown to be as effective as imipenem as monotherapy in treating severe nosocomial pneumonia [23] . In a multicenter study of 189 patients with severe hospital-(84%) or communityacquired (1 6%) pneumonia, intravenous ciprofloxacin at high doses (400 mg every 8 h) resulted in significantly better rates of clinical cure or improvement than that achieved with imipenem (1 g every 8 h) and a significantly higher rate of bacteriologic eradication [24] . This was thought to result from the significantly higher rate of bacteriologic eradication of Enterobacteriaceae in the ciprofloxacin group (93% versus 6696, p=0.001 
COMMUNITY-ACQUIRED PNEUMONIA Definition and diagnosis
Pneumonia is defined as inflammation and consolidation of the lung tissue due to an infectious agent. (1 993) Uncomphc.irrd piieunionu of unknown etiology without features Indic-mng severe 01-iioii~pneuiiiococc.il dis I'refe1-1-ec1: a n aniinoprnicillin (miosycilhn 500 iiig orally t.i.d. or mipicillin 500 iiig 1V q.i.d. or benzylpcnic~llin 1.2 g IV q.i.d.) Altrriim~c\: cr\:tliron~ycin (500 iiig orallv or IV q.i.d.) or secondor third-generation cephalosporin (cctiii-oxiin~ or cehtxuiiiie) 1'rc.fci-reii: erythi-oniycin (1 g IV c1.i.d.) + \rcoiidL 01-tliii-d-getirr'itioii cwphalocporiii (cehirosniir I i g 01-crfot.i\imc 2 g 1V t.i ii i
Altcrnati\-e: ampicillin I 2, fluclosnrilliii 2 9, a n d erythuoniycin 1 g, ~l l Streptococcus pneurnoniae. Table 3 summarizes the in vitro activity of one of the established fluoroquinolones, ciprofloxacin, and the activities of three new fluoroquinolones, levofloxacin, sparfloxacin and trovafloxacin against the main respiratory tract pathogens [19,32-401. Ciprofloxacin has been extensively prescribed in the treatment of LRTIs [41]. However, a succession of anecdotal reports of relatively poor performance of ciprofloxacin against Stveptoccccus pneumoniae led to a change in the package labeling in the USA, cautioning against the use of currently a.iailable fluoroquinolones in the treatment of pneumococcal infections [42-451. This was also partly responsible for an increase in the recommended dosage regimen of intravenous ciprofloxacin from 200 mg twice daily to 400 mg twice or three times daily.
Several studies have reported the use of ofloxacin in the treatment of CAP In a comparative study with erythromycin, Nielsen et a1 showed combined cure/ improvement rates of 96% for ofloxacin and 82% for erythromycin [46] . Plouffe et a1 showed that ofloxacin was as effective as standard therapy (p-lactam alone or plus a niacrolide) in patients hospitalized for CAP (clinical success rates of 92% and 87%, respectively) [47] . An overall satisfactory response rate of 93% in 212 patients was reported by Petermann [27] .
Carbon et a1 compared temafloxacin and amoxycillin in a study of 246 hospitalized patients [48] . Overall, there were no significant differences between temafloxacin and amoxycillin in clinical recovery rates (8596, 80%) and bacterial eradication rates (98%, 96%). Both were equally effective in treating pneumococcal infections. Although several additional studies demonstrated the efficacy of temafloxacin in CAP, this antibiotic was withdrawn from use in 1992 due to the high incidence of serious adverse events.
Sparfloxacin is active against all major LRTI pathogens, including atypical organisms such as L. pneumophila, Mycoplasrna pneumoniae and Chlarnydia pneumoniae [49] . However, severe phototoxic reactions have been associated with its use which have led to prescribing restrictions. Sparfloxacin shows rapid and high diffusion into respiratory tract tissues and fluids, with concentrations of 2.6 mg/L in bronchial mucosa, 9.8 mg/L in the epithelial lining fluid and 61.3 mg/L in alveolar macrophages 12 h after an oral loading dose of 400 mg [50] .
Several studies in CAP have been performed with this antibiotic. Two double-blind studies compared the efficacy of sparfloxacin (200 mg once daily, following a 400-mg loading dose) with that of amoxycillin/ clavulanic acid (500/125 mg three times daily), erythromycin (1000 mg twice daily) or amoxycillin (1000 mg three times daily) [51] . The results of these studies were pooled to encompass 1137 episodes of CAP in hospitalized patients (560 were treated with sparfloxacin and 577 were randomized to the comparator agents), showing that sparfloxacin had similar efficacy to that of the comparators, with global efficacy rates of 88% and 84%, respectively.
Another study compared sparfloxacin 200 mg once daily with a combination of amoxycillin 1 g three times daily and ofloxacin 200 mg twice daily for 10 days [52] . The placebo-controlled, double-blind randomized study was conducted in 21 1 hospitalized elderly patients or in cases of first antibiotic treatment failure. O f the isolated pathogens, 40% and 36% were identified as Streptococcus pneumoniae in the sparfloxacin and amoxycillin plus ofloxacin groups, respectively. At the end of treatment, the overall efficacy rates (defined as successful clinical cure and resolution or improvement of signs or symptoms) for the sparfloxacin and amoxycillin plus ofloxacin treatment groups were 92% and 8296, respectively. Oral treatment with sparfloxacin in CAP (caused by Streptococcus pneumoniae in 20% of cases) has also been shown to be superior to roxithromycin (82%1 success rate versus 72%) in another controlled study of 304 patients [53]. Levofloxacin, the /-isomer of oflosacin, is generally twice as potent as ofloxacin, with a broad range of activity against most Gran-negative and Gram-positive bacteria, including atypical organisms 1341. Like that of ofloxacin, the oral bioavailability of levofloxacin approaches IOO' X), perniitting oral dosing for all but the most seriously ill and debilitated patients [54, 55] . In addition, levofloxacin has good penetration into lung tissue, bronchial mucosa, epithelial lining fluid and alveolar niacrophages after a 500-mg single dose. In a mouse pneumonia niodel, oral levofloxacin (20 and 40 mg/kg) significantly reduced the number of viable Strcptororcrrs pnerm~iniae organisms in the lungs, whereas ciprofloxacin was n o more effective than n o therapy 1341, Animal studies and recent pharmacokinetic studies in humans also suggest that, unlike enoxacin or ciprofloxacin, levofloxacin does not significantly impair theophylline metabolism [34, 56] . Levofloxacin may also have a much lower potential for photosensitivity reactions in comparison with other fluoroquinolones, such as loniefloxacin, sparfloxacin and enoxacin [57] .
Two published studies have demonstrated the efficacy of levofloxacin in CAP In an open, noricomparative, multicenter study in 68 patients, intravenou? or oral levofloxacin once daily was highly effective in mild-to-moderate and severe CAI', with a successful clinical response in 100% of the 60 clinically evaluable patients [58] . A l l the pathogens isolated in this study, including Streptococcus pnenmonine, H . ir$ueizzue, Stnphylorocrirs unreiis and Cklnniydin pueumoniae, were eradicated. Intravenous or oral levofloxacin (500 m g once daily) waE compared with parenteral ceftriaxone (1-2 g once or twice daily) and/or cefuroxime axetil (SO0 nig twice daily) in a randomized, open label, active-control trial in patients with a primary diagnosis of CAP 1591. Patients received the study medications for 7-1 4 days; levofloxacin 500 nig once daily either as a 1-h infusion or orally; ceftriaxone 1 or 2 g once or twice daily; oral cefuroxiine axeti1 500 m g twice daily. Cherall, 456 patient$ were evaluable fbr efficacy (226 Ievofloxacin, 230 ceftriaxone/cefuroxime). Clinical succcss (defined as cure or iniprovernent) was achieved in 96% of patients treated with levofloxacin and 90% of those treated with ceftriax-one/cefui-ox-ime. The pretreatment pathogen was eradicated in 98% of those treated with levofloxacin cainpared with 85% of those treated with ceftriaxone/cefuroxinie. An eradication rate of 100% was achieved for the two most comiiion pretreatment pathogens, Stveptoroccus prieunzorzine and H . inPuerzzm, in the levofloxacin treatment group compared with 94% and 79'%,, respectively, in the ceftriaxone/cefuroxime group. Levofloxacin was well tolerated, with nausea (2%) and diarrhea (1%) being the most common adverse events.
Trovafloxacin has comparable activity to ciprofloxacin against H . ir!flirr.nznc and :\foomxc//n ratnrrlinlis, and improved xtivity apinst Streptocorrrrr pncririiorriac and group A streptococci 1401. In addition, it is highly active against L;yiofre//n spp. m d CIiImnjdin pnPrrrnorrine and equally effective agaiiist both penicilliii-susceptible and -resistant pneumococci. T h e potent in vitro activity of trovafloxacin against pneuniococci and other respiratory tract pathogens is currently being assessed in clinical trials.
CONCLUSIONS
The diverse nature of LKTI pathogens and the need for empirical treatnient, especially i n CAP, necessitates the use of an antibiotic with a spectrum adapted to the range of pulmonary pathogens, T h e increasing probleni of resistance to currently used antibiotics necessitates the use of alternative agents. T h e new fluoroquinolones, in contrast to ciprofloxacin, xvhich does not have reliable antipneumococcal activity? have a broad antibacterial spectrum, enhanced activity aaainst Stveptncoccur pririr~mniar, and rapid bactericidal activity. Spafloxacin was the first of these new agents to be introduced and there are niaiiy compounds currently in development. Levofloxacin, which has recently become available in the USA, has a similar safety profile to ofloxacin, appears to be well tolerated and is not associated with the phototoxicity problenis reported with spaifloxacin.
T h e newer fluoroquinolones could be considered for first-line monotherapy for coinniunity-acquired LRTI because o f their wide spectrum of activity, clinical efficacy and good safety profile. In nosocomial pneumonia, however, because of the prevalence of P neviigirrora or Srnph y/orocurs iiiireiis as causative pathogens, the results of susceptibility tests and of clinical studies should determine the therapy to be srlccted. Confirmation of their cost-etkctiveiiess is required in CAP but, :it present. the results of the necessary pharmacoecono~nic studies are not available. They could also be used ;IS second-line therapy, in cases of failure with other antibiotics, cuch as niacrolidey or B-lactanis. Currently thwe is insufiicient inforn~tiori to support their use in combination therapy. Hoxvevcr, in the case of levofloxacin, there are considerable supporting data on the u!;e of ofloxacin in combination therapy. T h e option of step-dwvn or switch therapy (from oral to intravenous administration or vice versa) is an iniportanr advantage of the new fluoroquinolones.
In order to deterniinc fully the place ofthese agents i n the treatment of lower respiratory tract infections, more studies are needed. These include studies to determine: the cost-effectiveness of fluoroquinolones compared with other agents; the optimal duration of treatment based on clinical endpoints rather than on fixed duration of treatment; the impact of the use of fluoroquinolones on the microbial ecology of the patient and people in close contact with the patient; and the pediatric use of fluoroquinolones, other than in cystic fibrosis. O n the basis of the information available to date, however, the new fluoroquinolones should prove to be useful agents for the treatment of lower respiratory tract infections.
